Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    19636010 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin Lymphoma
Intervention: Drug: SGN-40 (anti-huCD40 mAb)

Indicates status has not been verified in more than two years